Evidence map›Paper›PMID 41863473›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2026

From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravis

Zhimin Chen, Xiaotong Kong, Ping He, Risu Na, Lihua Wang

Abstract readValidation Study
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhimin ChenDepartment of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, 150086, China.
Xiaotong KongDepartment of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, 150086, China.
Ping HeDepartment of Neurology, The First Hospital of Harbin, Harbin, 150010, China.
Risu NaDepartment of Geriatric Medicine, Tongliao People's Hospital, Tongliao, 020800, China.
Lihua WangDepartment of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, 150086, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCircRNAs are implicated in various autoimmune diseases, such as Myasthenia Gravis (MG), yet their regulatory mechanisms remain poorly understood. This research investigated the regulatory network of circRNAs, miRNAs, and mRNAs in modulating MG progression. MATERIALS AND

methodsThree MG patients (male: female = 1:2) and three healthy controls were enrolled for microarray analysis. The “Limma” package was employed to identify the differentially expressed circRNAs (DECs). Target miRNAs of DECs were predicted via the CircInteractome database, while target genes of miRNAs were predicted utilizing miRWalk, miRTarbase, and TargetScan databases. Cytoscape software was applied to establish the circRNAs-miRNAs-mRNAs network. Thereafter, a dual-luciferase reporter assay was conducted to validate the targeted regulatory relationship between hsa_circ_0062400, hsa_circ_0002397, and miR-338-3p. The expression of NRP1 was measured by qRT-PCR and Western blotting, and the cell viability of Jurkat cells was evaluated via CCK-8 assay. The levels of cytokines (IL-2, IL-6, IFN-γ, TNF-α) after NRP1 knockout were detected by ELISA.

results4 circRNAs, 2 miRNAs, and 11 target genes associated with MG pathogenesis were identified to construct a ceRNA regulatory network. In-vitro assays validated the targeted interactions between hsa_circ_0062400, hsa_circ_0002397, and miR-338-3p. miR-338-3p negatively regulated both protein and mRNA levels of NRP1. Further, silencing hsa_circ_0062400 or hsa_circ_ 0002397 markedly suppressed NRP1 expression and Jurkat cell proliferation, which was reversed by miR-338-3p inhibitor. Moreover, NRP1 affected the levels of cytokines in Jurkat cells. DISCUSSION: The circRNAs were demonstrated to be closely associated with MG etiology, which was also supported by our current discovery that hsa_circ_0062400 and hsa_circ_0002397 regulated the level of NRP1 by sponging miR-338-3p in MG. However, the roles of hsa_circ_0062400 and hsa_circ_0002397 in MG have been rarely reported, which requires further validation. Limitations of this study included a small, gender-imbalanced sample size for microarray analysis and incomplete verification of the ceRNA network. In addition, functional experiments were limited to Jurkat cells, and more in-vivo validation assays were lacking.

conclusionCollectively, the present study revealed MG pathogenesis and also provided potential treatment targets for the disease.

Indexed as

MicroRNAsMyasthenia GravisNeuropilin-1RNA, CircularAdultCase-Control StudiesFemaleGene Regulatory NetworksHumansJurkat CellsMaleMiddle AgedMicroRNAsMIR338, humanNeuropilin-1RNA, Circularhsa_circ_0002397hsa_circ_0062400miR-338-3pMyasthenia gravisNRP1therapeutic targets.

Identifiers

PMID41863473
PMCPMC13284659

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.